Revenue
2020
2021
2022
2023
2024
2025
Mirum Pharmaceuticals, Inc. (MIRM)
Price$89.70Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $521.3M | $336.9M | $186.4M | $77.1M | $19.1M | $0 | — |
| Research & development | $186.2M | $140.6M | $102.6M | $106.8M | $131.4M | $81.6M | $43.0M |
| Operating expenses | $543.4M | $424.5M | $295.5M | $208.3M | $192.6M | $104.3M | $54.7M |
| Operating income | −$22.1M | −$87.6M | −$109.2M | −$131.2M | −$173.4M | −$104.3M | −$54.7M |
| Operating margin | −4.25% | −26.00% | −58.57% | −170.28% | −906.12% | — | — |
| EBITDA | $2.1M | −$64.0M | −$98.3M | −$128.0M | −$172.8M | −$104.0M | −$54.6M |
| EBITDA margin | 0.40% | −18.99% | −52.76% | −166.08% | −903.01% | — | — |
| Net income | −$23.4M | −$87.9M | −$163.4M | −$135.7M | −$84.0M | −$103.3M | −$52.6M |
| Net profit margin | −4.48% | −26.10% | −87.68% | −176.05% | −438.85% | — | — |
| Basic EPSper basic share | -$0.47 | -$1.85 | -$4.00 | -$4.01 | -$2.77 | -$4.09 | -$4.58 |
| Diluted EPSper diluted share | -$0.47 | -$1.85 | -$4.00 | -$4.02 | -$2.77 | -$4.09 | -$4.58 |
Owners
Reported shareholders
11.86%of listed shares
Frazier Life Sciences Management, L.P.7.68M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Frazier Life Sciences Management, L.P. | 11.86%7.68M shares |
Jupiter Topco LLC | 9.13%5.91M shares |
BlackRock, Inc. | 6.78%4.39M shares |
Heron Patrick J | ≈6.23%4.03M shares |
FMR LLC | 5.67%3.67M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 4.10%2.66M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.67%2.38M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.48%2.25M shares |
STATE STREET CORP | 3.35%2.17M shares |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2.17%1.4M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.15%1.39M shares |
Invesco Ltd. | 2.11%1.36M shares |
WELLINGTON MANAGEMENT GROUP LLP | 2.02%1.31M shares |
EVENTIDE ASSET MANAGEMENT, LLC | 1.93%1.25M shares |
TANG CAPITAL MANAGEMENT LLC | 1.91%1.24M shares |
Capital World Investors | 1.78%1.15M shares |
FRANKLIN RESOURCES INC | 1.78%1.15M shares |
NOVO HOLDINGS A/S | 1.74%1.13M shares |
TCG Crossover Management, LLC | 1.64%1.06M shares |
BVF INC/IL | 1.63%1.06M shares |
Percentages use 64.75M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 · 10b5-1 | Howe JolandaSVP, GLOBAL CONTROLLER | SellCommon Stock | 2.6K | $101.95 | $264.5K | 5.8K |
| Jun 8, 2026Form 4 · 10b5-1 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER | SellCommon Stock | 1.6K | $95.12 | $149.1K | 44.8K |
| Jun 8, 2026Form 4 · 10b5-1 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER | SellCommon Stock | 1.2K | $93.95 | $110.4K | 46.4K |
| Jun 8, 2026Form 4 · 10b5-1 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER | SellCommon Stock | 2.3K | $92.84 | $209.6K | 47.5K |
| Jun 1, 2026Form 4 · 10b5-1 | Peetz ChristopherCHIEF EXECUTIVE OFFICER | SellCommon Stock | 883 | $99.66 | $88.0K | 194.3K |
Community posts
Mirum’s hepatitis-delta drug succeeds in Phase 3 AZURE-1
Mirum Pharmaceuticals ($MIRM) said brelovitug met the primary endpoint in the Phase 3 portion of AZURE-1, which enrolled 153 treatment-naive patients with chronic hepatitis delta. At 24 weeks, the combined viral-response and liver-enzyme-no ...
